论文部分内容阅读
造血细胞表达谱系专一性抗原是单克隆抗体靶向治疗恶性血液肿瘤的理想靶点。基因工程技术的发展为降低单克隆抗体的免疫源性,加强单克隆抗体对肿瘤细胞的杀伤作用提供了有力的手段。针对CD20、CD52、CD33的工程抗体Rituximab、Campath—1H和Mylotary已应用于临床治疗,在低度滤泡性非霍奇金淋巴瘤、慢性淋巴细胞白血病和急性髓系白血病的治疗中取得了良好的效果。
Hematopoietic cell lineage-specific antigens are the ideal targets for the targeted therapy of hematologic malignancies with monoclonal antibodies. The development of genetic engineering technology to reduce the immunogenicity of monoclonal antibodies and enhance the killing effect of monoclonal antibodies on tumor cells provides a powerful tool. Engineered antibodies to CD20, CD52, CD33 Rituximab, Campath-1H and Mylotary have been used clinically for treatment and have achieved good results in the treatment of low-grade follicular non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia Effect.